Investigational Cancer Drug

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerInfluenzaChickenpox

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Tecentriq

Roche

Preclinical

362

Investigational Cancer Drug

GSK

Phase 3

13

Lexiscan

Astellas

Preclinical

14

Adenocard

Astellas

Preclinical

15

Methylthioninium Chloride

PProvepharm SAS

Preclinical

36

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

37

Effexor

WWyeth-Lederle Vaccines

Preclinical

28

Tricor

JJagotec

Preclinical

19

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

110

Avastin

Roche

Preclinical

4Show 16 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Influenza5 trials

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Completed·GSK·Phase 1·NCT01934127·427 enrolled

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

Completed·GSK·Phase 2·NCT01949090·363 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

Withdrawn·GSK·Phase 1·NCT02177734

Show 2 more trials

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Completed·GSK·Phase 1·NCT01659086·422 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Completed·GSK·Phase 1·NCT01999842·424 enrolled

Chickenpox5 trials

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Recruiting·GSK·Phase 3·NCT06693895·750 enrolled

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Completed·GSK·Phase 2·NCT05630846·801 enrolled

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting·GSK·Phase 3·NCT06740630·1,840 enrolled

Show 2 more trials

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Completed·GSK·Phase 2·NCT05084508·800 enrolled

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting·GSK·Phase 3·NCT06806137·600 enrolled

Breast Cancer1 trial

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

Completed·GSK·Phase 2·NCT00051103

Prevention1 trial

Prevention of Seasonal Affective Disorder

Completed·GSK·Phase 3·NCT00046449

Immune Response1 trial

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

Active, not recruiting·GSK·Phase 1·NCT06573281·213 enrolled

Details

Drug Info

Related News